ResMed Inc. (FRA:RME)

ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of EUR 32.20 billion. The enterprise value is 31.74 billion.

Market Cap	32.20B
Enterprise Value	31.74B

Important Dates

The next estimated earnings date is Thursday, January 22, 2026.

Earnings Date	Jan 22, 2026
Ex-Dividend Date	Nov 13, 2025

Share Statistics

Current Share Class	145.97M
Shares Outstanding	n/a
Shares Change (YoY)	-0.28%
Shares Change (QoQ)	-0.09%
Owned by Insiders (%)	0.53%
Owned by Institutions (%)	69.00%
Float	145.05M

Valuation Ratios

The trailing PE ratio is 26.28 and the forward PE ratio is 22.97.

PE Ratio	26.28
Forward PE	22.97
PS Ratio	7.19
PB Ratio	6.17
P/TBV Ratio	14.37
P/FCF Ratio	21.37
P/OCF Ratio	20.06
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.58, with an EV/FCF ratio of 21.06.

EV / Earnings	25.90
EV / Sales	7.00
EV / EBITDA	18.58
EV / EBIT	20.83
EV / FCF	21.06

Financial Position

The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.14.

Current Ratio	2.89
Quick Ratio	1.87
Debt / Equity	0.14
Debt / EBITDA	0.43
Debt / FCF	0.48
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 25.41% and return on invested capital (ROIC) is 16.93%.

Return on Equity (ROE)	25.41%
Return on Assets (ROA)	14.18%
Return on Invested Capital (ROIC)	16.93%
Return on Capital Employed (ROCE)	24.99%
Revenue Per Employee	422,725
Profits Per Employee	115,616
Employee Count	10,600
Asset Turnover	0.68
Inventory Turnover	2.03

Taxes

In the past 12 months, ResMed has paid 258.21 million in taxes.

Income Tax	258.21M
Effective Tax Rate	17.40%

Stock Price Statistics

The stock price has decreased by -9.32% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-9.32%
50-Day Moving Average	224.07
200-Day Moving Average	220.13
Relative Strength Index (RSI)	43.17
Average Volume (20 Days)	42

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.05

Income Statement

In the last 12 months, ResMed had revenue of EUR 4.48 billion and earned 1.23 billion in profits. Earnings per share was 8.33.

Revenue	4.48B
Gross Profit	2.72B
Operating Income	1.50B
Pretax Income	1.48B
Net Income	1.23B
EBITDA	1.65B
EBIT	1.50B
Earnings Per Share (EPS)	8.33

Balance Sheet

The company has 1.18 billion in cash and 721.35 million in debt, giving a net cash position of 458.11 million.

Cash & Cash Equivalents	1.18B
Total Debt	721.35M
Net Cash	458.11M
Net Cash Per Share	n/a
Equity (Book Value)	5.22B
Book Value Per Share	35.75
Working Capital	2.02B

Cash Flow

In the last 12 months, operating cash flow was 1.61 billion and capital expenditures -98.01 million, giving a free cash flow of 1.51 billion.

Operating Cash Flow	1.61B
Capital Expenditures	-98.01M
Free Cash Flow	1.51B
FCF Per Share	n/a

Margins

Gross margin is 60.69%, with operating and profit margins of 33.52% and 27.35%.

Gross Margin	60.69%
Operating Margin	33.52%
Pretax Margin	33.11%
Profit Margin	27.35%
EBITDA Margin	36.87%
EBIT Margin	33.52%
FCF Margin	33.64%

Dividends & Yields

This stock pays an annual dividend of 2.01, which amounts to a dividend yield of 0.91%.

Dividend Per Share	2.01
Dividend Yield	0.91%
Dividend Growth (YoY)	7.61%
Years of Dividend Growth	3
Payout Ratio	22.31%
Buyback Yield	0.28%
Shareholder Yield	1.19%
Earnings Yield	3.81%
FCF Yield	4.68%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on August 31, 2010. It was a forward split with a ratio of 2.

Last Split Date	Aug 31, 2010
Split Type	Forward
Split Ratio	2

Scores

ResMed has an Altman Z-Score of 12.67 and a Piotroski F-Score of 6.

Altman Z-Score	12.67
Piotroski F-Score	6